Table 1 Baseline characteristics of patients treated with antifibrotic agents
Factor | Group | Overall (n = 100) |
|---|---|---|
Age | 68 [64, 73] | |
 Age ≥ 65 yrs. (%) | Yes | 73 (73.0) |
 Sex (%) | Male | 75 (75.0) |
 Smoking history (%) | Yes | 69 (69.0) |
 Clinical diagnosis | IPF | 75 (75) |
| Â | others | 25 (25) |
 SLB (%) | Yes | 29 (29.0) |
 Commodity index |  | 1.0 [1.0, 1.0] |
 TTE RVSP | ≥40 mmHg | 29 (29.0) |
 FVC % predicted |  | 70.8 [58.7, 82.4] |
 FVC % predicted < 70 | Yes | 48 (48.0) |
 DLCO % predicted |  | 55.9 [45.1, 68.4] |
 DLCO % predicted < 55 | Yes | 45(45.0) |
 ILD-GAP score |  | 3 [2, 4] |
 ILD-GAP score | 0–3 | 61 (61.0) |
|  | 4–5 | 31 (31.0) |
6–8 | 8 (8.0) | |
 LTOT | No use | 63 (63.0) |
| Â | Introduce at same time | 29 (29.0) |
Prior to antifibrotic agent | 8 (8.0) | |
 KL6 |  | 1265 [804, 2046] |
 LDH | 239.5 [208, 265] | |
 Time from diagnosis to antifibrotic agent (per month) | 12 [6, 36] | |
Medication | ||
 Antifibrotic agent | Nintedanib | 52 (52.0) |
| Â | Pirfenidone | 48 (48.0) |
 H2 blocker use | Yes | 12 (12) |
 PPI use | Yes | 62 (62) |
 Corticosteroid use | Yes | 26 (26) |
 Corticosteroid dose | mg/body/day | 0 [0, 5] |
 Corticosteroid dose in patients receiving corticosteroids | Mg/body/day | 10[10, 20] |
 Anticoagulant (%) | Yes | 18 (18.0) |